YOLFTbeta
69

Bonraybio Co., Ltd.

6955 · TW · Healthcare / Medical Devices

89.20TWD+1.20 (+1.36%)

Price History

Full chart

Market Stats

Previous Close88.00
Open89.10
Day Range89.10 – 89.20
52-Week Range88.17 – 141.59
Volume4.00K
Market Cap2.87B
P/E (TTM)26.56
Forward P/E0.00
EPS3.52
Dividend Yield1.20%
Beta0.10
50-Day Avg97.76
200-Day Avg117.75

About

Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test kits; and S10 data consolidation software. Bonraybio Co., Ltd. was founded in 2015 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Zhenteng Xu
  • HeadquartersNo. 118, Gongye 9th Road, Taichung, Taiwan, 41280, Taiwan
  • Websitehttps://bonraybio.com

Leadership

  • Mr. Zhenteng XuChairman & GM
  • Ms. Peizhen YangAccounting Supervisor, Deputy GM of Admin and Head of Corporate Governance & Information Security
  • Mr. Yingzhi LiaoExecutive VP and Head of R&D

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue56.30M106.27M159.64M222.88M306.31M
Growth (%)-+88.78%+50.22%+39.61%+37.43%
Cost of Revenue16.72M25.68M39.85M47.92M67.79M
Gross Profit39.58M80.59M119.79M174.96M238.52M
Gross Margin70.30%75.83%75.04%78.50%77.87%
Operating Expense78.08M87.23M98.45M114.01M138.57M
Operating Income-38.50M-6.64M21.34M60.95M99.95M
Operating Margin-68.40%-6.25%13.37%27.35%32.63%
EBITDA-11.38M36.61M80.39M118.35M
EBITDA Margin-10.70%22.93%36.07%38.64%
Net Income-31.71M1.69M25.73M68.36M102.50M
Net Income Margin-56.34%1.59%16.11%30.67%33.46%
R&D43.84M39.51M41.12M41.76M54.83M
R&D as % of Total Revenue77.87%37.18%25.75%18.74%17.90%
Interest Expense209.00K153.00K218.00K175.00K132.00K
Interest Expense % of Total Revenue0.37%0.14%0.14%0.08%0.04%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets262.61M280.03M317.26M622.80M719.87M
Total Liabilities25.61M27.23M38.81M51.45M78.47M
Total Equity236.99M252.80M278.46M571.35M641.41M
Cash70.02M89.42M116.87M410.17M271.25M

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-25.09M11.98M26.89M80.14M99.99M
Capital Expenditure4.64M7.96M9.75M11.03M34.24M
Free Cash Flow-29.73M4.02M17.14M69.11M65.75M
Dividends Paid---3.42M32.35M
FCF to OCF118.49%33.59%63.74%86.24%65.76%
Dividend Paid to FCF---4.94%49.20%

Key Statistics & Ratios

Market Cap2.87B
Enterprise Value2.38B
Trailing P/E26.56
Forward P/E0.00
Price / Sales8.63
Price / Book4.44
EPS3.52
Book Value21.62
Revenue (TTM)332.21M
Gross Profit (TTM)257.03M
EBITDA114.99M
Profit Margin32.50%
Operating Margin33.05%
Return on Equity17.39%
Return on Assets9.70%
Shares Outstanding30.66M
Shares Float15.32M
Beta0.10
Dividend Yield1.20%
Dividend Rate1.50
Payout Ratio0.00%

Dividends

20261×
1.50Mar 19, 2026
20252×
1.50Mar 27, 20251.06Mar 26, 2025
20241×
0.12Apr 18, 2024

Stock Splits

  • Aug 26, 20261236250:1000000
  • Aug 25, 20251150:1000
  • Jul 22, 20241155000:1000000